EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study)
Key facts
- Who runs it
- University Hospital, Geneva
- Where
- Switzerland5 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 170 people, planned
- Started
- 5 Jun 2026
- Expected to end
- 30 Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- PCR multiplex BioFire Pneumonia plus
- Record updated
- 29 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Adult patients (≥ 18 years old)
- Hospitalized in intensive care with invasive mechanical ventilation ≥ 48 hours
- Administration of antimicrobial therapy for suspected VAP at the time of inclusion
- Expected survival > 96 hours
Who cannot take part
- Enrollment prior to the current trial
- Participation in an interventional study on the management of AMR that has a direct impact on antibiotic therapy practices
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The objective of the study is to determine whether rapid multiplex PCR testing of respiratory samples can reduce exposure to broad-spectrum antibiotics in intensive care unit patients with suspected or confirmed ventilator-associated pneumonia, compared to standard diagnostic methods.
Read full original descriptionShow less
As secondary objectives, the investigators will study antibiotic management and overall antibiotic consumption, as well as escalation or de-escalation events. The investigators will study the potential clinical impact of using multiplex PCR to see if the length of stay in the intensive care unit is reduced, as well as the duration of mechanical ventilation.
The 2 groups in the trial
- Control GroupNo study treatment, for comparison
Care in the control group is based on international guidelines for the management of VAP and carried out in accordance with the local guidelines of each center. This includes respiratory samples with traditional cultures to identify pathogens associated with VAP.
- Intervention GroupTreatment being tested
In the intervention arm, in addition to traditional cultures for identifying pathogens and their resistance, multiplex PCR will be performed on the patient's respiratory samples. Empirical antibiotic therapy will be directly adapted to the results of multiplex PCR according to the guidelines provided.
Treatment: PCR multiplex BioFire Pneumonia plus
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- EARLY Antibiotics aDaptation in Ventilator-Acquired-Pneumonia Treatment After Implementation of a Broad-Panel Respiratory Multiplex PCR Test: A Multicenter Randomized Control Trial Conducted In Swiss Intensive Care Units. The EARLY ADAPT Study.
- Record updated
- 29 April 2026